By InvitationPhase 3

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

United States90 participantsStarted 2019-10-30

Plain-language summary

The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures.
✓. Subject must have completed all 24 weeks of participation in the study C-935788-057.

What they're measuring

Adverse Events

Timeframe: 104 weeks

Blood Pressure

Timeframe: 104 weeks

Absolute Neutrophil Count (ANC)

Timeframe: 104 weeks

Trial details

NCT IDNCT04138927

SponsorRigel Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-04

View on ClinicalTrials.gov More Warm Antibody Autoimmune Hemolytic Anemia trials